Marshall Wace
ALLO icon

Marshall Wace’s Allogene Therapeutics ALLO Stock Holding History

Marshall Wace’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.41M Buy
3,447,984
+3,162,423
+1,107% +$6.34M 0.01% 1058
2025
Q4 		$391K Buy
+285,561
New +$377K ﹤0.01% 2349
2023
Q4 		– Sell
-228,642
Closed -$725K – 2135
2023
Q3 		$725K Buy
228,642
+185,296
+427% +$812K ﹤0.01% 1599
2023
Q2 		$215K Sell
43,346
-391,674
-90% -$2.12M ﹤0.01% 2230
2023
Q1 		$2.15M Buy
+435,020
New +$2.79M ﹤0.01% 1419
2022
Q4 		– Sell
-12,593
Closed -$136K – 2897
2022
Q3 		$136K Buy
+12,593
New +$171K ﹤0.01% 3147
2022
Q1 		– Sell
-948,624
Closed -$14.2M – 3301
2021
Q4 		$14.2M Buy
+948,624
New +$16.7M 0.03% 643
2021
Q3 		– Sell
-456,591
Closed -$11.9M – 2977
2021
Q2 		$11.9M Buy
+456,591
New +$13M 0.05% 403
2020
Q2 		– Sell
-132,006
Closed -$2.57M – 1509
2020
Q1 		$2.57M Sell
132,006
-21,099
-14% -$503K 0.03% 546
2019
Q4 		$3.98M Buy
+153,105
New +$4.22M 0.03% 606
2019
Q3 		– Sell
-19,524
Closed -$525K – 1651
2019
Q2 		$525K Sell
19,524
-42,118
-68% -$1.17M ﹤0.01% 1072
2019
Q1 		$1.78M Buy
+61,642
New +$1.79M 0.02% 778

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace's ALLO Position: Q1 2026 in Review

Marshall Wace increased its Allogene Therapeutics (ALLO) stake by 1,107% in Q1 2026, buying an estimated $6.34M and bringing the position to 3,447,984 shares worth $8.41M. The position accounts for 0.01% of the portfolio, ranked #1058.

Marshall Wace first reported a position in ALLO in Q1 2019 and has held it in 12 quarters since. The position peaked at $14.2M in Q4 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Marshall Wace held 3,447,984 shares of Allogene Therapeutics worth $8.41M as of Q1 2026.
  • Marshall Wace bought 3,162,423 Allogene Therapeutics shares in Q1 2026, an estimated $6.34M.
  • Allogene Therapeutics made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1058 holding.
  • Marshall Wace first reported a position in Allogene Therapeutics in Q1 2019 and has held it in 12 quarters since.
  • Marshall Wace's Allogene Therapeutics position peaked at $14.2M in Q4 2021.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.